查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1456965

全球輸血診斷市場 - 2024 年至 2029 年預測

Global Blood Transfusion Diagnostics Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年輸血診斷市場規模為42.3億美元，預估在預測期間內複合年成長率為6.07%，至2029年市場總規模達63.89億美元。

輸血診斷是指在輸血給病人之前對血液或血液成分進行的檢查。為了避免副作用和感染疾病傳播，必須對每個血液單位進行血型和疾病篩檢。它是輸血治療的重要組成部分，因為它為醫療保健專業人員提供重要資訊並檢驗捐贈者和受血者血液樣本的兼容性。紅血球是最常輸注的血液製品。分子血型診斷是輸血診斷的一種。對於具有臨床相關、稀有或弱抗原抗體的患者，分子血型可以實現更安全的血液儲存和按需供應。

開發中國家缺乏足夠的血庫、輸血所需的醫療設備以及適當的血液儲存條件，限制了血液供應以滿足高需求。醫院缺乏進行衛生和安全輸血的必要設備。因此，慢性病負擔的增加和捐贈者篩檢需求的增加正在推動市場的成長。此外，由於外傷、交通事故和外科手術導致的輸血需求不斷增加，也對市場產生了積極影響。

市場領先的先進分子平台的出現正在加速從手動測試和儀器向半自動化和全自動儀器的轉變。這些自動化系統對於檢測血液樣本中的輸血傳染感染疾病(TTI) 至關重要，並且可以準確消除整個輸血過程中的人為錯誤。

在預測期內，北美預計將成為輸血診斷市場最大的區域市場。這一優勢得益於輸血程序接受度的提高、公眾對捐血意識的提高以及醫療基礎設施的發展。根據國家生物技術資訊中心公佈的資料，美國每年輸血量超過1,500萬單位，全球整體估計有8,500萬單位輸血量。

市場促進因素：

  • 對血液和血液成分的高需求預計將推動市場成長。

血友病、癌症、血小板減少性疾病和慢性腎臟病（CKD）等血液相關疾病的盛行率不斷上升，增加了對輸血的需求。根據世界腎臟日估計，2020年全球約有8.5億人將患有腎臟疾病。慢性腎臟病(CKD) 影響十分之一的人，預計到 2040年終將成為第六大死因。此外，越來越多的貧血患者需要輸紅血球進行治療，進一步推動了對輸血診斷的需求。世界衛生組織 (WHO) 估計全球約有 16.2 億人患有貧血症。再加上已開發國家和開發中國家透過各種措施提高了對感染疾病血液安全的認知，正在推動對血液篩檢測試和其他診斷設備的需求。

市場限制因素：

  • 設備高成本、基礎設施缺乏

儘管慢性血液疾病的盛行率不斷上升，輸血需求不斷增加，但仍有幾個問題阻礙了市場的成長。造成這種情況的原因之一是缺乏對衛生基礎設施的投資和嚴格的政府政策，特別是與開發中國家。此外，測試、設備和試劑的高成本以及缺乏處理自動化診斷解決方案的合格專業人員也是限制輸血診斷市場在預測期內成長的因素。

競爭考察：

州輸血委員會 (SBTC)相關人員於 2021 年 9 月報告稱，馬哈拉斯特拉邦的血庫僅夠一周的供應。這一下降是由於捐血減少、大流行導致的捐血者減少以及全州辦公室和設施的關閉。

2021 年 9 月，美國紅十字會發起了一項新的全國舉措，旨在接觸更多黑人捐血，幫助鐮狀疾病患者並改善他們的健康狀況。不僅血型相同，而且種族和民族相同的人的捐血是治療鐮狀細胞患者的最可靠的選擇。

主要進展

  • 2023 年 3 月 - MedGenome Labs 推出 FSHD1 基因篩檢測試，即光學基因組圖譜測試 (OGM)，以評估 1 型面肩肱型肌肉肌肉萎縮症(FSHD1) 患者的早期基因變化。這種先進的診斷工具採用先進的技術來全面、準確地評估遺傳變化，檢測大規模插入和重複以及細微的 DNA 變化。
  • 2021 年 5 月 - F. Hoffmann-La Roche Ltd 和 Bio-Rad Laboratories, Inc. 合作，為客戶提供 Bio-Rad 的 InteliQ 產品和 Unity QC資料管理解決方案。此合作夥伴關係旨在提高工作流程效率並提高實驗室的分析效能。 Bio-Rad 的 InteliQ 產品（包括帶條碼的品管管）是此合作夥伴關係的一部分。

目錄

第1章 簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • CXO觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球輸血診斷市場：依類型

  • 介紹
  • 裝置
  • 套件和試劑

第6章全球輸血診斷市場：依技術分類

  • 介紹
  • ELISA
  • 西方印漬術
  • 核酸擴增
  • 其他

第7章全球輸血診斷市場：依最終使用者分類

  • 介紹
  • 醫院/診所
  • 診斷實驗室
  • 血庫

第8章全球輸血診斷市場：按地區

  • 介紹
  • 北美洲
  • 南美洲
  • 歐洲
  • 中東/非洲
  • 亞太地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Quotient Ltd.
  • BAG Healthcare
  • Abbott
  • Immucor
  • Diasorin SPA
  • Bio-Rad Laboratories Inc.
  • Grifols SA
  • F. Hoffmann La Roche Ltd.
  • Beckman Coulter Inc.
  • DIAGAST
簡介目錄
Product Code: KSI061611612

The global blood transfusion diagnostics market was valued at US$4.230 billion in 2022 and is expected to grow at a CAGR of 6.07% over the forecast period to reach a total market size of US$6.389 billion by 2029.

Blood transfusion diagnostics refers to testing conducted on blood and blood components before transfusion to patients. To avoid adverse reactions or infection transmission, each blood unit must be checked for blood group type and disease screening. It is an essential component of transfusion treatment since it offers vital information to healthcare practitioners and validates the compatibility of donor and recipient blood samples. Red blood cells are the most frequently transfused blood products. Molecular blood group diagnosis is one of the transfusion diagnostics. For patients with antibodies against clinically relevant, uncommon, or weak antigens, molecular blood group diagnosis allows for safer blood storage and on-demand supplies.

Developing and underdeveloped countries lack proper blood banks, medical equipment required for blood transfusion, adequate conditions for blood storage, and a limited supply of blood in response to high demand. Hospitals lack the necessary amenities to deliver hygienic and safe transfusions. Thus, the escalating burden of chronic disorders and the rising need for donor screening are boosting the market's growth. Furthermore, the rising need for transfusions because of trauma, car accidents, and surgical procedures is favorably influencing the market.

The emergence of advanced molecular platforms by market leaders accelerates the transition from manual testing and equipment to semi-automated and fully automated devices. These automated systems have been critical in detecting transfusion transmissible infections (TTIs) in blood samples and can accurately remove human error throughout the transfusion procedure.

During the forecast period, North America is expected to be the largest regional market for the global blood transfusion diagnostics market. This dominance can be attributed to increased acceptance of the blood transfusion procedure, increased public awareness regarding blood donations, and developed healthcare infrastructure. According to data released by the National Center for Biotechnology Information, over 15 million blood units are transfused in the United States each year, with an estimated 85 million units transfused globally.

MARKET DRIVER:

  • Blood and blood components are in high demand is anticipate in the market growth

The rising prevalence of blood-related conditions such as hemophilia, cancer, thrombocytopenia, and others, as well as chronic kidney disease (CKD), has increased the demand for blood transfusions. According to World Kidney Day estimates, about 850 million individuals worldwide will be suffering from kidney diseases in 2020. In addition, one out of every ten individuals has chronic kidney disease (CKD), which is predicted to become the sixth leading cause of death by the end of 2040. Furthermore, the growing number of patients suffering from anemia necessitates red blood cell transfusion for treatment, which is further driving up the demand for blood transfusion diagnostics. The World Health Organization (WHO) estimates that anaemia affects around 1.62 billion people worldwide. This, together with increased awareness regarding blood safety from infectious diseases through various initiatives in developed and developing nations, is driving up demand for blood screening tests and other diagnostic instruments.

MARKET RESTRAINTS:

  • The high cost of instruments and a lack of infrastructure

Despite the rising prevalence of chronic blood disorders and increased demand for blood transfusions, several issues are impeding the market's growth. One of the causes is a lack of investment in healthcare infrastructure and strict government policies, particularly in developing nations when compared to developed countries. Furthermore, the high cost of tests, instruments, and reagents, along with a shortage of qualified professionals to handle automated diagnostic solutions, is one of the factors restraining the growth of the blood transfusion diagnostics market during the forecast period.

Competitive insight:

Officials from the State Blood Transfusion Council (SBTC) reported in September 2021 that supplies in Maharashtra blood banks would barely last a week. This drop was attributed to a decrease in blood donation camps, reduced donor footfall owing to the pandemic, and the closure of offices and institutions in the state.

The American Red Cross started a new nationwide initiative in September 2021 to reach out to more black blood donors to aid patients with sickle cell disease and improve health outcomes. Blood donations from individuals of the same race or ethnicity as well as blood type are the most reliable option to treat sickle cell patients.

Key Developments:

  • March 2023- MedGenome Labs has introduced the FSHD1 genetic screening test, the Optical Genome Mapping Test (OGM), to assess early-stage genetic changes in patients with Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1). This advanced diagnostic tool uses advanced technology to provide a comprehensive and accurate assessment of genetic changes, detecting both large-scale insertions and duplications, as well as subtle DNA changes.
  • May 2021- F. Hoffmann-La Roche Ltd and Bio-Rad Laboratories, Inc. have partnered to offer customers access to Bio-Rad's InteliQ products and Unity QC data management solutions. The partnership aims to enhance workflow efficiency and improve analytical performance in laboratories. Bio-Rad's InteliQ products, including barcoded quality control tubes, are part of the alliance.

Segmentation:

By Type

  • Instruments
  • Kits & Reagents

By Technology

  • ELISA
  • Western Blotting
  • Nucleic Acid Amplification
  • Others

By End-User

  • Hospitals & Clinics
  • Diagnostic Labs
  • Blood Banks

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • France
  • Germany
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY TYPE

  • 5.1. Introduction
  • 5.2. Instruments
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Kits & Reagents
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. ELISA
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Western Blotting
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Nucleic Acid Amplification
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Others
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness

7. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Diagnostic Labs
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Blood Banks
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL BLOOD TRANSFUSION DIAGNOSTICS MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Technology
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Technology
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Technology
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Italy
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Spain
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
      • 8.4.4.6. Others
        • 8.4.4.6.1. Market Opportunities and Trends
        • 8.4.4.6.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Technology
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Others
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Technology
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. Japan
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. China
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. India
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Quotient Ltd.
  • 10.2. BAG Healthcare
  • 10.3. Abbott
  • 10.4. Immucor
  • 10.5. Diasorin SPA
  • 10.6. Bio-Rad Laboratories Inc.
  • 10.7. Grifols S.A.
  • 10.8. F. Hoffmann La Roche Ltd.
  • 10.9. Beckman Coulter Inc.
  • 10.10. DIAGAST